Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment

NCT01895439 is registered in ClinicalTrials.gov with University of Jordan as lead sponsor.

NCT NCT01895439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment
Lead sponsor
University of Jordan
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2012
Completion date
February 29, 2016
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis